诱导多能干细胞
免疫系统
间充质干细胞
细胞生物学
干细胞
胚胎干细胞
细胞疗法
生物
胞外囊泡
癌症研究
小RNA
免疫学
微泡
生物化学
基因
作者
Jana Zarubova,Mohammad Mahdi Hasani‐Sadrabadi,Yutong Wu,Graciel Diamante,Jenny Cheng,Soomin Park,Xiao Han,Fatemeh Sadat Majedi,Li Yang,Olivia Wang,In Sook Ahn,Cade M. Matherne,Jia Fan,Jianyi Zhang,Xiaojun Lance Lian,Zhen Gu,Manish J. Butte,Reza Ardehali,Peter C. Butler,Tony Ye Hu
标识
DOI:10.1038/s41565-026-02320-z
摘要
Abstract Embryos can achieve immune tolerance, yet the underlying mechanisms remain incompletely understood. Here, we demonstrate that pluripotent stem cells (PSCs), including embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), secrete extracellular vesicles (EVs) that markedly outperform mesenchymal stem cell (MSC)–derived EVs in suppressing pro-inflammatory cytokine secretion, inhibiting activated T-cell proliferation, and inducing regulatory T-cell (Treg) formation through CDK8 downregulation. Nuclear magnetic resonance (NMR) analysis reveals distinct molecular fingerprints of PSC EVs compared to those of MSC EVs. Moreover, comparative analyses show that PSC EVs contain unique proteins and microRNAs, such as the pluripotency-associated proteins ROR1 and CD133 and members of the miR-302 family, which are not found in MSC EVs, as determined by proteomic profiling and microRNA sequencing. Notably, the dynamic suspension culture of PSC aggregates significantly increases EV yield, offering a scalable and reproducible source superior to other cell sources. To evaluate their therapeutic potential, we employed an antigen-specific type 1 diabetes model and found that two local injections of iPSC EVs, particularly when delivered via a biomaterial scaffold, significantly enhanced diabetes-free survival. These treatments increased Treg populations in draining lymph nodes, induced systemic immunomodulation, and preserved β-cell mass from immune-mediated destruction. The immunomodulatory capability of PSC EVs suggests broad applications in treating autoimmune diseases and supporting stem cell-derived cell therapies by promoting immune tolerance. Their scalability, consistency, and superior therapeutic properties position PSC EVs as a compelling platform for next-generation immunotherapies and cell-based treatment strategies.
科研通智能强力驱动
Strongly Powered by AbleSci AI